JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Home
Signaling Pathways

Signaling Pathways

A3012 Ruxolitinib (INCB018424)
4 Citation

Target: JAK

Summary: JAK inhibitor

insoluble in H2O; ≥15.32 mg/mL
A4135 Tofacitinib (CP-690550) Citrate
2 Citation

Target: JAK

Summary: Potent JAK inhibitor

≥25.22 mg/mL
A4136 TG101348 (SAR302503)
2 Citation

Target: FLT3|JAK|c-RET

Summary: JAK-2 inhibitor,potent and selective

≥26.23 mg/mL
A4139 AG-490
3 Citation

Target: EGFR|JAK

Summary: JAK2/EGFR inhibitor

insoluble in H2O; ≥14.7 mg/mL
A4193 SMI-4a

Target: Pim

Summary: Potent Pim inhibitor

insoluble in H2O; ≥13.65 mg/mL
A3320 CO-1686 (AVL-301)
1 Citation

Target: EGFR

Summary: EGFR inhibitor

≥27.8 mg/mL
A3433 Gefitinib hydrochloride

Target: EGFR

Summary: Potent EGFR inhibitor

insoluble in EtOH; ≥4.28 mg/mL
B4970 HO-3867
1 Citation

Target: STAT

Summary: STAT3 inhibitor, selective

insoluble in EtOH; insoluble in H2O; ≥18.15 mg/mL
B2283 Niclosamide

Target: STAT

Summary: Inhibitor of the STAT3 signaling pathway
A3937 XL019

Target: JAK

Summary: JAK2 inhibitor,potent and selective

insoluble in EtOH; insoluble in H2O; ≥11.125 mg/mL